BackChromocell Therapeutics Overview

Chromocell Therapeutics EBIT

EBIT (Earnings Before Interest and Taxes) analysis for CHRO.

Quarterly EBIT

$0.00

As of Mar 31, 2026

Annual EBIT (TTM)

-$33.40M
↓ 269.55% YoY

Trailing 12 months ending Mar 31, 2026

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

Jump to metric
Total RevenueCost of RevenueGross ProfitResearch & DevelopmentSelling, General & AdminOperating IncomeOther Income Expense NetEBITIncome TaxNet IncomeProfit Margin